News Sentiment

TLSI sentiment intelligence

TriSalus Life Sciences Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 4.14 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

76/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-11.7% over one week, +9.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 76/100 classification
One-week reaction -11.7% Price reacting lower
Trend fit Trend inactive 9.8% over four weeks
Fair value -27.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 32
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 8
TradingView 5
TradingKey 4
www.marketscreener.com 3
GlobeNewswire 2
GuruFocus.com 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 15
Analyst action 4
Regulatory and legal 3
Deals and strategy 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
TradingView Direct company coverage

Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI

This article provides financial information for TriSalus Life Sciences, Inc. (NASDAQ: TLSI) on TradingView. It specifically highlights the company's "Price to sales forward" metric, displayed within the financials section of its profile. The content indicates market data and refe

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 19:40
Source
TradingView
Stock Titan Direct company coverage

TLSIW SEC Filings - TriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms

This page on StockTitan provides access to TriSalus Life Sciences Inc. (TLSIW) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. Each filing is accompanied by an AI-generated summary, sentiment analysis, impact scores, and end-of-day st

Tone
Positive 63/100
Event
Earnings
Published
10 Jul 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

First Light Asset Management, Mathew Arens report 10.74% stake in TriSalus (TLSI)

First Light Asset Management, LLC and Mathew P. Arens have jointly reported a beneficial ownership of 6,596,242 shares of TriSalus Life Sciences, Inc. (TLSI), representing a 10.74% stake. This disclosure, an amendment to a prior Schedule 13G filing, indicates shared voting and di

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 20:42
Source
Stock Titan
Stock Titan Direct company coverage

TriSalus (TLSI) CFO has shares withheld to cover RSU tax obligations

TriSalus Life Sciences, Inc. (TLSI) Chief Financial Officer David Patience had 14,650 shares of common stock withheld at $4.46 per share to cover tax obligations from the vesting of restricted stock units. This was a routine tax-related share withholding, not an open-market sale.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:09
Source
Stock Titan
Finviz Direct company coverage

TLSI - TriSalus Life Sciences Inc Volatility & Greeks

This article provides a detailed financial overview of TriSalus Life Sciences Inc (TLSI), including its current stock price, market capitalization, income, sales, and various financial ratios. It also presents volatility metrics, insider and institutional ownership, and performan

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 13:11
Source
Finviz
www.marketscreener.com Direct company coverage

TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell 3000E Value Benchmark

TriSalus Life Sciences, Inc. (NasdaqGM:TLSI) has been removed from the Russell 3000E Value Benchmark, alongside other Russell indices such as the Russell Small Cap Comp Value, Russell 3000 Value, Russell 2500 Value, Russell Microcap Value, and Russell 2000 Value Benchmark. This o

Tone
Negative 18/100
Event
Market update
Published
01 Jul 2026 23:44
Source
www.marketscreener.com
Stock Titan Direct company coverage

TriSalus (TLSI) CEO Mary Szela acquires 3,990 ESPP shares, now holds 1.08M

TriSalus Life Sciences CEO Mary T. Szela acquired 3,990 shares of common stock at $3.87 per share through the company's Employee Stock Purchase Plan (ESPP). This transaction, exempt under Rule 16b-3, increases her direct holdings to 1,077,683 TriSalus shares. The acquisition high

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

TriSalus Life Sciences (TLSI) CCO acquires 561 ESPP shares

TriSalus Life Sciences (TLSI) Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.87 per share through the company’s Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increases his direct holdings to 128,319 shares. The filing

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI

This article provides the "Price to earnings forward" value for TriSalus Life Sciences, Inc. (NASDAQ: TLSI). The specific value for this financial metric is not disclosed in the provided content, but the article indicates it is a historical value without current trading data. It

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 05:41
Source
TradingView
Stock Titan Direct company coverage

TriSalus Life Sciences (TLSI) CMO awarded RSUs and 120,000-share option grant

TriSalus Life Sciences' Chief Medical Officer, Richard Henry, has been awarded new equity compensation including 60,000 restricted stock units and an option grant for 120,000 shares of common stock at an exercise price of $4.74 per share. These awards are subject to vesting sched

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 00:40
Source
Stock Titan
Stock Titan Direct company coverage

TriSalus (TLSI) CMO discloses common stock and option holdings in Form 3

TriSalus Life Sciences, Inc.'s new Chief Medical Officer, Marshall Richard Henry, has disclosed his initial equity holdings via a Form 3 filing, effective June 29, 2026. The filing reveals he holds 30,000 shares of common stock acquired before his appointment, along with employee

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:40
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 TriSalus Life Sciences Inc For: 29 June By Investing.com

This article from Investing.com reports on a Form 4 filing for TriSalus Life Sciences Inc. on June 29, 2026. The brief piece includes the stock ticker TLSI and its price performance, but provides no further details about the content of the Form 4 filing.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 18:40
Source
Investing.com Canada
www.marketscreener.com Direct company coverage

TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell Small Cap Comp Value Benchmark

TriSalus Life Sciences, Inc. (NasdaqGM:TLSI) has been removed from the Russell Small Cap Comp Value Benchmark. The company's stock experienced a 9.61% increase despite this news. This development follows recent announcements of the company being dropped from other Russell benchma

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 10:11
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

TriSalus Life Sciences, Inc.(NasdaqGM: TLSI) dropped from Russell 2500 Value Benchmark

TriSalus Life Sciences, Inc. (NasdaqGM: TLSI) has been removed from the Russell 2500 Value Benchmark index. This news, published on June 28, 2026, also noted related updates, including the company's prior removal from the Russell 3000 Value Benchmark. TriSalus Life Sciences is an

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 21:12
Source
www.marketscreener.com
TradingView Direct company coverage

TriSalus Life Sciences, Inc. Actuals & Estimates (NASDAQ:TLSI)

This article provides an overview of TriSalus Life Sciences, Inc. (TLSI) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report dates. The article als

Tone
Positive 62/100
Event
Earnings
Published
26 Jun 2026 09:40
Source
TradingView
TradingView Direct company coverage

TLSI Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for TriSalus Life Sciences, Inc. (TLSI) stock, including analyst ratings, historical price performance, and financial data. It indicates that 5 analysts offer a price target with a max estimate of $11.00 and a min estimate of $7.00

Tone
Positive 66/100
Event
Analyst action
Published
26 Jun 2026 04:40
Source
TradingView
PR Newswire Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI

Pomerantz LLP is investigating TriSalus Life Sciences Inc. (NASDAQ: TLSI) on behalf of investors for potential securities fraud. This investigation follows TriSalus's announcement of lower-than-expected Q1 2026 revenue and a reduced full-year revenue guidance, primarily due to co

Tone
Negative 19/100
Event
Regulatory and legal
Published
25 Jun 2026 10:00
Source
PR Newswire
TradingKey Direct company coverage

TriSalus Life Sciences Inc (TLSIW) Institutional Confidence

This article provides details on the institutional confidence in TriSalus Life Sciences Inc. (TLSIW), listing institutional holdings and changes in share percentages. Several large institutions have significantly reduced their stakes, while others like Fort Baker Capital Manageme

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 12:10
Source
TradingKey
TradingKey Direct company coverage

TriSalus Life Sciences Inc (TLSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of TriSalus Life Sciences Inc (TLSI), noting its current price momentum score of 7.30 and its trading range between a resistance level of $4.56 and a support level of $3.12. It details various technical indicators and moving averages, wh

Tone
Negative 38/100
Event
Market update
Published
18 Jun 2026 06:09
Source
TradingKey
TradingKey Direct company coverage

TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates

TriSalus Life Sciences Inc (TLSI) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have a consensus price target of $11.00 for TLSI, with most recommending a "Buy" rating. The company's expected revenue for the ne

Tone
Positive 75/100
Event
Earnings
Published
18 Jun 2026 02:09
Source
TradingKey
TradingKey Direct company coverage

TriSalus Life Sciences Inc (TLSIW) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a brief overview of TriSalus Life Sciences Inc. (TLSIW) focusing on its dividend and stock split history. It states that no dividend payments or stock splits have been recorded for the company. The page also displays current stock price information and links

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 16:40
Source
TradingKey
GlobeNewswire Direct company coverage

TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm has announced an investigation into TriSalus Life Sciences, Inc. (NASDAQ: TLSI) for potential securities law violations. This follows TriSalus's Q1 2026 financial results, which showed a year-over-year revenue decline and a cut in full-year guidance, attribute

Tone
Negative 5/100
Event
Regulatory and legal
Published
17 Jun 2026 13:40
Source
GlobeNewswire
Medical Product Outsourcing Direct company coverage

Richard Marshall Accepts New Role at TriSalus Life Sciences

Richard Marshall, M.D., has been appointed Chief Medical Officer at TriSalus Life Sciences, effective June 29, 2026. Dr. Marshall, previously the company's medical director since January 2025, will now lead the medical strategy and clinical leadership for TriSalus, focusing on ad

Tone
Positive 70/100
Event
Market update
Published
16 Jun 2026 14:38
Source
Medical Product Outsourcing
Stock Titan Direct company coverage

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

TriSalus Life Sciences announced a virtual KOL event on June 24, 2026, to discuss new real-world evidence for its Pressure-Enabled Drug Delivery (PEDD) technology in liver cancer. The study shows a 48% improvement in drug delivery to target tumors and reduced complications, with

Tone
Positive 71/100
Event
Analyst action
Published
10 Jun 2026 12:08
Source
Stock Titan